Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma

PURPOSE: BRAF inhibitors are clinically active in patients with advanced BRAF(V600)-mutant melanoma, although acquired resistance remains common. Preclinical studies demonstrated that resistance could be overcome using concurrent treatment with the HSP90 inhibitor XL888. METHODS: Vemurafenib (960 mg...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Eroglu, Zeynep, Chen, Y. Ann, Gibney, Geoffrey T., Weber, Jeffrey S., Kudchadkar, Ragini R., Khushalani, Nikhil I., Markowitz, Joseph, Brohl, Andrew S., Tetteh, Leticia F., Ramadan, Howida, Arnone, Gina, Li, Jiannong, Zhao, Xiuhua, Sharma, Ritin, Darville, Lancia N.F., Fang, Bin, Smalley, Inna, Messina, Jane L., Koomen, John M., Sondak, Vernon K., Smalley, Keiran S.M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6195480/
https://ncbi.nlm.nih.gov/pubmed/29674508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0565
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg